2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders
- 24 April 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 58 (1) , 46-50
- https://doi.org/10.1111/j.1600-0609.1997.tb01409.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine TherapyNew England Journal of Medicine, 1994
- Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemiaEuropean Journal of Haematology, 1993
- 2-Chlorodeoxyadenosine for Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1993
- 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignanciesBritish Journal of Cancer, 1993
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- Deoxycoformycin in the treatment of mature B-cell malignanciesBritish Journal of Cancer, 1990
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988
- Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.Journal of Clinical Investigation, 1985
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984